雖然對 B 型肝炎和愛滋病毒的血液檢查已成為血庫的例行檢查。初
期感染的人們具有空窗期無法由陽性檢測出病毒，因此仍然有風險存在。
另外，全血只能在 1〜6°C 下保存 1 個月。因此，除了傳統的輸血方式外，
還必須開發新的血液替代品以應對血液供應不足和因輸血可能引起的病
毒感染。現今，基於血紅蛋白（Hb）的血液替代品的發展已經解決了 Hb
四聚體解離為二聚體的問題，然而，在缺乏 2,3-DPG 調節的情況下，它
們無法釋放適量的氧氣。此外，Hb 與一氧化氮（NO）之間的高反應速
率會導致 metHb 的形成以及血管收縮和血壓的升高。為了降低 Hb-NO 氧
化速率，我們在 α 鏈（29Leu→Phe）和 β 鏈（67Trp→Phe）中進行了點
突變。為了清除超氧化物並將 metHb 還原為 oxyHb，將 α-1-微球蛋白（α1M）
基因與 Hbβ 融合，於是建構了 pETite-Hbβ(67Trp→Phe)- α1M/synoα（29Leu
→Phe）質體。

Although the blood tests for hepatitis B or HIV have become a routine in
blood banks. A window period that people in early infection couldn’t test
positive remains as a health threat. In addition, whole blood can only be
stored for 1 month at 1 ~ 6 ° C. Therefore, in addition to traditional blood
transfusions, new blood substitutes must also be developed to cope with
insufficient blood supply and possible virus infection due to transfusion. The
developments of hemoglobin (Hb)-based blood substitutes today have
resolved the problem of the disassociation of Hb tetramers into dimers,
However, in the absence of 2,3-DPG regulation, they cannot release an
appropriate amount of oxygen. Also, the high reaction rate between Hb and
nitric oxide (NO) leads to the formation of metHb and the increase of
vasoconstriction and blood pressure. In order to reduce the Hb-NO rate, we
performed point mutations in the α chain (29Leu → Phe) and β chain (67Trp
→ Phe). To scavenge superoxide and reduce metHb to oxyHb, the
alpha-1-microglobulin (α1M) gene was fused to Hbβ. In this study, we have
constructed pETite-Hbβ (67Trp→Phe)- α1M/synoα (29Leu→Phe) plasmid
for expressing Hbs.

目錄
摘要....................................................................................................................I
目錄.................................................................................................................IV
圖目錄........................................................................................................... VII
表目錄.............................................................................................................IX
英文縮寫全名對照表...................................................................................... X
壹、緒論........................................................................................................... 1
一、前言................................................................................................... 1
二、文獻回顧........................................................................................... 3
1.Hb 的結構與功能.......................................................................... 3
2.以血紅素溶液進行輸血之副作用................................................ 5
3.化學修飾的血紅素........................................................................ 6
4.基因重組的血紅素........................................................................ 9
5.A1M 合成及蛋白質的結構與功能............................................ 13
三、研究動機......................................................................................... 15
四、實驗設計......................................................................................... 15
貳、實驗儀器、器材與藥品......................................................................... 18
一、實驗儀器......................................................................................... 18
二、實驗器材......................................................................................... 20
三、實驗藥品......................................................................................... 21
參、實驗藥品配製與步驟............................................................................. 28
一、抗生素配製..................................................................................... 28
Kanamycin stock solution(100 mg/mL) ......................................... 28
二、培養液配製..................................................................................... 28
Luria-Bertani broth (LB) medium................................................... 28
LB-kanamycin (100μg/mL) agar plates.......................................... 28
SOC medium................................................................................... 29
V
SOC-kanamycin (50 μg/mL) agar plate.......................................... 30
三、菌種的培養與保存......................................................................... 30
DH5α 之培養.................................................................................. 30
SHuffle T7 E. coli 之培養 .............................................................. 30
菌種保存......................................................................................... 31
重組血紅素的質體純化................................................................. 31
四、聚合酶連鎖反應(polymerase chain reaction；PCR) .................... 32
Primer 的稀釋................................................................................. 32
pETite-β67W-A1M 載體的複製.................................................... 32
synoα 片段的複製.......................................................................... 32
五、質體和 PCR 產物限制酶處理(Restriction enzyme digestion) ..... 34
裁切酵素反應................................................................................. 34
PCR 溶液與 DpnI 酵素反應.......................................................... 34
Exonclease III 接合反應................................................................. 35
六、DNA 電泳 ....................................................................................... 36
0.5X TAE buffer 的配製................................................................. 36
配製瓊脂膠片................................................................................. 36
瓊脂膠純化..................................................................................... 36
七、大腸桿菌轉型................................................................................. 37
DH5α E. coli 轉型 .......................................................................... 37
SHuffle T7 Express E. coli 轉型..................................................... 37
八、蛋白質表達與純化......................................................................... 38
誘導藥品配置................................................................................. 38
SHuffle T7 Express E. coli 小量誘導............................................. 38
高溫破菌......................................................................................... 39
SDS 藥品配置 ................................................................................ 40
SDS-PAGE 蛋白質電泳鑄造及操作............................................. 40
SDS-PAGE 染色及脫色................................................................. 41
肆、實驗結果與討論..................................................................................... 43
一、pETite-Hb(β67W-A1M- synoα-α29F)質體建構............................ 43
1.pETite-Hb(β67W-A1M)載體的複製 .......................................... 43
2.synoα(α29F)片段的複製............................................................. 46
3.β-A1M 載體與 α 片段的接合..................................................... 49
二、pETite-Hbβ(67Trp→Phe)-A1M- synoα-α29F 質體建構............... 50
三、pETite-Hb(β67W-A1M- synoα-α29F)不同溫度下小量誘導之蛋白
質表現..................................................................................................... 53
VI
四、pETite-Hbβ(67Trp→Phe)-A1M- synoα-α29F 不同溫度下小量誘
導之蛋白質表現..................................................................................... 56
五、以 PMSF 溶液對 pETite-Hbβ(67Trp→Phe)-A1M- synoα -α29F 的
保護作用................................................................................................. 58
六、pETite-Hbβ(67Trp→Phe)-A1M- synoα-α29F 定序結果............... 59
伍、結論及未來展望..................................................................................... 61
參考文獻......................................................................................................... 62

[1] J. Y. Chen, M. Scerbo, and G. Kramer, "A review of blood substitutes:
examining the history, clinical trial results, and ethics of
hemoglobin-based oxygen carriers," Clinics (Sao Paulo), vol. 64, no. 8,
pp. 803-13, 2009, doi: 10.1590/S1807-59322009000800016.
[2] S. A. Gould and G. S. Moss, "Clinical development of human
polymerized hemoglobin as a blood substitute," (in eng), World J Surg,
vol. 20, no. 9, pp. 1200-7, Nov-Dec 1996, doi:
10.1007/s002689900183.
[3] L. Liu, J. L. Martínez, Z. Liu, D. Petranovic, and J. Nielsen, "Balanced
globin protein expression and heme biosynthesis improve production of
human hemoglobin in Saccharomyces cerevisiae," (in eng), Metab Eng,
vol. 21, pp. 9-16, Jan 2014, doi: 10.1016/j.ymben.2013.10.010.
[4] J. L. Martínez, L. Liu, D. Petranovic, and J. Nielsen, "Engineering the
oxygen sensing regulation results in an enhanced recombinant human
hemoglobin production by Saccharomyces cerevisiae," (in eng),
Biotechnol Bioeng, vol. 112, no. 1, pp. 181-8, Jan 2015, doi:
10.1002/bit.25347.
[5] R. F. Xu, J. W. Zhang, P. H. Zhou, R. Yang, X. Y. Feng, and L. X. Xu,
"A novel artificial red blood cell substitute: grafted starch-encapsulated
hemoglobin," (in English), RSC Adv., Article vol. 5, no. 54, pp.
43845-43853, 2015, doi: 10.1039/c5ra00772k.
[6] S. Maijaroen, P. Anwised, S. Klaynongsruang, S. Daduang, and A.
Boonmee, "Comparison of recombinant α-hemoglobin from
Crocodylus siamensis expressed in different cloning vectors and their
biological properties," (in eng), Protein Expr Purif, vol. 118, pp. 55-63,
Feb 2016, doi: 10.1016/j.pep.2015.09.028.
[7] Q. Wang et al., "Bioinspired Polydopamine-Coated Hemoglobin as
Potential Oxygen Carrier with Antioxidant Properties," (in eng),
Biomacromolecules, vol. 18, no. 4, pp. 1333-1341, Apr 10 2017, doi:
10.1021/acs.biomac.7b00077.
[8] S. Faggiano, S. Bruno, L. Ronda, P. Pizzonia, B. Pioselli, and A.
Mozzarelli, "Modulation of expression and polymerization of
hemoglobin Polytaur, a potential blood substitute," Arch Biochem
Biophys, vol. 505, no. 1, pp. 42-7, Jan 1 2011, doi:
10.1016/j.abb.2010.09.027.
[9] P. W. Buehler, F. D'Agnillo, and D. J. Schaer, "Hemoglobin-based
oxygen carriers: From mechanisms of toxicity and clearance to rational
drug design," (in eng), Trends Mol Med, vol. 16, no. 10, pp. 447-57,
Oct 2010, doi: 10.1016/j.molmed.2010.07.006.
[10] M. G. Olsson et al., "Pathological conditions involving extracellular
hemoglobin: molecular mechanisms, clinical significance, and novel
therapeutic opportunities for α(1)-microglobulin," (in eng), Antioxid
Redox Signal, vol. 17, no. 5, pp. 813-46, Sep 1 2012, doi:
10.1089/ars.2011.4282.
[11] S. Kumar and U. Bandyopadhyay, "Free heme toxicity and its
detoxification systems in human," (in eng), Toxicol Lett, vol. 157, no. 3,
pp. 175-88, Jul 4 2005, doi: 10.1016/j.toxlet.2005.03.004.
[12] M. Allhorn, A. Klapyta, and B. Akerström, "Redox properties of the
lipocalin alpha1-microglobulin: reduction of cytochrome c, hemoglobin,
and free iron," (in eng), Free Radic Biol Med, vol. 38, no. 5, pp. 557-67,
Mar 1 2005, doi: 10.1016/j.freeradbiomed.2004.12.013.
[13] E. Karnaukhova, S. Rutardottir, M. Rajabi, L. Wester Rosenlof, A. I.
Alayash, and B. Akerstrom, "Characterization of heme binding to
recombinant alpha1-microglobulin," Front Physiol, vol. 5, p. 465, 2014,
doi: 10.3389/fphys.2014.00465.
[14] D. Qi, P. Wang, C. Chen, S. Guo, and X. Wang, "Polymerization of
modified diaspirin cross-linked hemoglobin (DCLHb) with
1,6-bismaleimic-hexane," Artif Cells Nanomed Biotechnol, vol. 44, no.
4, pp. 1069-74, Jun 2016, doi: 10.3109/21691401.2016.1138488.
[15] N. Roamcharern et al., "Physicochemical properties and oxygen
affinity of glutaraldehyde polymerized crocodile hemoglobin: the new
alternative hemoglobin source for hemoglobin-based oxygen carriers,"
(in eng), Artif Cells Nanomed Biotechnol, vol. 47, no. 1, pp. 852-861,
Dec 2019, doi: 10.1080/21691401.2019.1579733.
[16] J. Monod, J. Wyman, and J. P. Changeux, "ON THE NATURE OF
ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL," (in eng), J
Mol Biol, vol. 12, pp. 88-118, May 1965, doi:
10.1016/s0022-2836(65)80285-6.
[17] M. K. Safo, M. H. Ahmed, M. S. Ghatge, and T. Boyiri,
"Hemoglobin-ligand binding: understanding Hb function and allostery
on atomic level," (in eng), Biochim Biophys Acta, vol. 1814, no. 6, pp.
797-809, Jun 2011, doi: 10.1016/j.bbapap.2011.02.013.
[18] B. Giardina, I. Messana, R. Scatena, and M. Castagnola, "The multiple
functions of hemoglobin," (in eng), Crit Rev Biochem Mol Biol, vol. 30,
no. 3, pp. 165-96, 1995, doi: 10.3109/10409239509085142.
[19] G. Panetta, A. Arcovito, V. Morea, A. Bellelli, and A. E. Miele,
"Hb(alphaalpha,betabeta): a novel fusion construct for a dimeric,
four-domain hemoglobin," Biochim Biophys Acta, vol. 1784, no. 10, pp.
1462-70, Oct 2008, doi: 10.1016/j.bbapap.2008.01.003.
[20] H. F. Bunn, "The use of hemoglobin as a blood substitute," (in eng), Am
J Hematol, vol. 42, no. 1, pp. 112-7, Jan 1993, doi:
10.1002/ajh.2830420122.
[21] C. Gaucher, E. Domingues-Hamdi, C. Prin-Mathieu, P. Menu, and V.
Baudin-Creuza, "Interaction of recombinant octameric hemoglobin
with endothelial cells," C R Biol, vol. 338, no. 2, pp. 95-102, Feb 2015,
doi: 10.1016/j.crvi.2014.11.004.
[22] N. Wajih et al., "The role of red blood cell S-nitrosation in nitrite
bioactivation and its modulation by leucine and glucose," Redox Biol,
vol. 8, pp. 415-21, Aug 2016, doi: 10.1016/j.redox.2016.04.004.
[23] X. Xu et al., "Measurements of nitric oxide on the heme iron and
beta-93 thiol of human hemoglobin during cycles of oxygenation and
deoxygenation," (in eng), Proc Natl Acad Sci U S A, vol. 100, no. 20,
pp. 11303-8, Sep 30 2003, doi: 10.1073/pnas.2033883100.
[24] R. E. Benesch and R. Benesch, "The mechanism of interaction of red
cell organic phosphates with hemoglobin," (in eng), Adv Protein Chem,
vol. 28, pp. 211-37, 1974, doi: 10.1016/s0065-3233(08)60231-4.
[25] J. Umbreit, "Methemoglobin--it's not just blue: a concise review," (in
eng), Am J Hematol, vol. 82, no. 2, pp. 134-44, Feb 2007, doi:
10.1002/ajh.20738.
[26] T. M. Chang, "Future prospects for artificial blood," (in eng), Trends
Biotechnol, vol. 17, no. 2, pp. 61-7, Feb 1999, doi:
10.1016/s0167-7799(98)01242-6.
[27] B. Yu, M. J. Raher, G. P. Volpato, K. D. Bloch, F. Ichinose, and W. M.
Zapol, "Inhaled nitric oxide enables artificial blood transfusion without
hypertension," Circulation, vol. 117, no. 15, pp. 1982-90, Apr 15 2008,
doi: 10.1161/CIRCULATIONAHA.107.729137.
[28] W. H. Chang, Y. Chang, Y. C. Chen, and H. W. Sung, "Hemoglobin
polymerized with a naturally occurring crosslinking agent as a blood
substitute: in vitro and in vivo studies," (in eng), Artif Cells Blood
Substit Immobil Biotechnol, vol. 32, no. 2, pp. 243-62, May 2004, doi:
10.1081/bio-120037830.
[29] F. Prouchayret, G. Fasan, M. Grandgeorge, C. Vigneron, P. Menu, and
E. Dellacherie, "A potential blood substitute from carboxylic dextran
and oxyhemoglobin. I. Preparation, purification and characterization,"
(in eng), Biomater Artif Cells Immobilization Biotechnol, vol. 20, no.
2-4, pp. 319-22, 1992, doi: 10.3109/10731199209119649.
[30] J. Zhang et al., "Conjugation with 20 kDa dextran decreases the
autoxidation rate of bovine hemoglobin," Artif Cells Nanomed
Biotechnol, vol. 46, no. 7, pp. 1436-1443, Nov 2018, doi:
10.1080/21691401.2017.1371184.
[31] A. G. Tsai, P. Cabrales, B. N. Manjula, S. A. Acharya, R. M. Winslow,
and M. Intaglietta, "Dissociation of local nitric oxide concentration and
vasoconstriction in the presence of cell-free hemoglobin oxygen
carriers," Blood, vol. 108, no. 10, pp. 3603-10, Nov 15 2006, doi:
10.1182/blood-2006-02-005272.
[32] J. Elmer, H. B. Alam, and S. R. Wilcox, "Hemoglobin-based oxygen
carriers for hemorrhagic shock," (in English), Resuscitation, Review
vol. 83, no. 3, pp. 285-292, Mar 2012, doi:
10.1016/j.resuscitation.2011.09.020.
[33] E. Tsuchida, K. Sou, A. Nakagawa, H. Sakai, T. Komatsu, and K.
Kobayashi, "Artificial oxygen carriers, hemoglobin vesicles and
albumin-hemes, based on bioconjugate chemistry," (in eng), Bioconjug
Chem, vol. 20, no. 8, pp. 1419-40, Aug 19 2009, doi:
10.1021/bc800431d.
[34] P. E. Graves, D. P. Henderson, M. J. Horstman, B. J. Solomon, and J. S.
Olson, "Enhancing stability and expression of recombinant human
hemoglobin in E. coli: Progress in the development of a recombinant
HBOC source," (in eng), Biochim Biophys Acta, vol. 1784, no. 10, pp.
1471-9, Oct 2008, doi: 10.1016/j.bbapap.2008.04.012.
[35] T. Kabbua, P. Anwised, A. Boonmee, B. P. Subedi, B. S. Pierce, and S.
Thammasirirak, "Autoinduction, purification, and characterization of
soluble alpha-globin chains of crocodile (Crocodylus siamensis)
hemoglobin in Escherichia coli," Protein Expr Purif, vol. 103, pp.
56-63, Nov 2014, doi: 10.1016/j.pep.2014.08.013.
[36] S. J. Hoffman et al., "Expression of fully functional tetrameric human
hemoglobin in Escherichia coli," (in eng), Proc Natl Acad Sci U S A,
vol. 87, no. 21, pp. 8521-5, Nov 1990, doi: 10.1073/pnas.87.21.8521.
[37] R. F. Eich et al., "Mechanism of NO-induced oxidation of myoglobin
and hemoglobin," (in eng), Biochemistry, vol. 35, no. 22, pp. 6976-83,
Jun 4 1996, doi: 10.1021/bi960442g.
[38] S. T. Jeong, N. T. Ho, M. P. Hendrich, and C. Ho, "Recombinant
hemoglobin(alpha 29leucine -> phenylalanine, alpha 96valine ->
tryptophan, beta 108asparagine -> lysine) exhibits low oxygen affinity
and high cooperativity combined with resistance to autoxidation," (in
English), Biochemistry, Article vol. 38, no. 40, pp. 13433-13442, Oct
1999, doi: 10.1021/bi991271t.
[39] M. F. Tam et al., "Autoxidation and oxygen binding properties of
recombinant hemoglobins with substitutions at the αVal-62 or βVal-67
position of the distal heme pocket," (in eng), J Biol Chem, vol. 288, no.
35, pp. 25512-21, Aug 30 2013, doi: 10.1074/jbc.M113.474841.
[40] A. B. Ramzi, J. E. Hyeon, and S. O. Han, "Improved catalytic activities
of a dye-decolorizing peroxidase (DyP) by overexpression of ALA and
heme biosynthesis genes in Escherichia coli," Process Biochemistry,
vol. 50, no. 8, pp. 1272-1276, 2015, doi:
10.1016/j.procbio.2015.05.004.
[41] D. M. Villarreal et al., "Enhancement of recombinant hemoglobin
production in Escherichia coli BL21(DE3) containing the Plesiomonas
shigelloides heme transport system," (in eng), Appl Environ Microbiol,
vol. 74, no. 18, pp. 5854-6, Sep 2008, doi: 10.1128/aem.01291-08.
[42] R. A. Zager, "Alpha 1 Microglobulin: A Potentially Paradoxical
Anti-Oxidant Agent," Adv Tech Biol Med, vol. 5, no. 3, Aug 2017, doi:
10.4172/2379-1764.1000238.
[43] M. Cederlund, A. Deronic, J. Pallon, O. E. Sørensen, and B. Åkerström,
"A1M/α1-microglobulin is proteolytically activated by
myeloperoxidase, binds its heme group and inhibits low density
lipoprotein oxidation," (in eng), Front Physiol, vol. 6, p. 11, 2015, doi:
10.3389/fphys.2015.00011.
[44] M. Allhorn, T. Berggård, J. Nordberg, M. L. Olsson, and B. Akerström,
"Processing of the lipocalin alpha(1)-microglobulin by hemoglobin
induces heme-binding and heme-degradation properties," (in eng),
Blood, vol. 99, no. 6, pp. 1894-901, Mar 15 2002, doi:
10.1182/blood.v99.6.1894.
[45] J. Lobstein, C. A. Emrich, C. Jeans, M. Faulkner, P. Riggs, and M.
Berkmen, "SHuffle, a novel Escherichia coli protein expression strain
capable of correctly folding disulfide bonded proteins in its cytoplasm,"
Microb Cell Fact, vol. 11, p. 56, May 8 2012, doi:
10.1186/1475-2859-11-56.